Status:
COMPLETED
Cancer Patients Treated With Immunotherapy in Intensive Care Unit
Lead Sponsor:
University Hospital, Grenoble
Collaborating Sponsors:
Jules Bordet Institute
Conditions:
Cancer
Critical Illness
Eligibility:
All Genders
18+ years
Brief Summary
This work aims to describe the characteristics and methods of management of patients suffering from a solid tumor treated with immunotherapy admitted to intensive care.
Detailed Description
The place of checkpoint inhibitors (anti-PD-1 and PD-L-1) is currently validated in the management of melanoma and metastatic non-small cell lung cancer. The toxicity profile is specific with adverse ...
Eligibility Criteria
Inclusion
- \> or = 18 years old;
- with a solid tumor;
- Treatment with anti-CTLA4 and / or anti-PD-1 / PDL-1 still in progress or up to 6 months after stopping;
- Admitted to resuscitation or continuous care in an unprogrammed way, whatever the reason.
Exclusion
- Minors;
- Pregnant or lactating woman;
- Admission after surgery of a scheduled surgery or for the security of procedure;
- Anti-CTLA4 and / or anti-PD-1 / PDL-1 treatment stopped for more than 6 months;
- Subject under guardianship or deprivation of liberty;
- Refusal of consent;
- No affiliation to a health insurance scheme.
Key Trial Info
Start Date :
September 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 23 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03357861
Start Date
September 1 2018
End Date
August 23 2021
Last Update
October 26 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Jules Bordet
Brussels, Belgium
2
UniversityHospitalGrenoble
Grenoble, France, 38043